158 related articles for article (PubMed ID: 16610973)
1. Gefitinib: an adverse effects profile.
Cersosimo RJ
Expert Opin Drug Saf; 2006 May; 5(3):469-79. PubMed ID: 16610973
[TBL] [Abstract][Full Text] [Related]
2. Gefitinib (Iressa) trials in non-small cell lung cancer.
Johnson DH
Lung Cancer; 2003 Aug; 41 Suppl 1():S23-8. PubMed ID: 12867059
[TBL] [Abstract][Full Text] [Related]
3. FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets.
Cohen MH; Williams GA; Sridhara R; Chen G; Pazdur R
Oncologist; 2003; 8(4):303-6. PubMed ID: 12897327
[TBL] [Abstract][Full Text] [Related]
4. Recurrent gefitinib-induced interstitial lung disease.
Suzuki M; Asahina H; Konishi J; Yamazaki K; Nishimura M
Intern Med; 2008; 47(6):533-6. PubMed ID: 18344641
[TBL] [Abstract][Full Text] [Related]
5. Rash as a surrogate marker for efficacy of epidermal growth factor receptor inhibitors in lung cancer.
Perez-Soler R
Clin Lung Cancer; 2006 Dec; 8 Suppl 1():S7-14. PubMed ID: 17239291
[TBL] [Abstract][Full Text] [Related]
6. Gefitinib therapy for non-small cell lung cancer.
Birnbaum A; Ready N
Curr Treat Options Oncol; 2005 Jan; 6(1):75-81. PubMed ID: 15610717
[TBL] [Abstract][Full Text] [Related]
7. Interstitial lung disease following erlotinib (Tarceva) in a patient who previously tolerated gefitinib (Iressa).
Tammaro KA; Baldwin PD; Lundberg AS
J Oncol Pharm Pract; 2005 Sep; 11(3):127-30. PubMed ID: 16390601
[TBL] [Abstract][Full Text] [Related]
8. Imaging patterns and prognosis of patients with gefitinib-related interstitial lung disease.
Yuan MK; Chang CY; Chang SC; Chang SJ; Tang GJ; Wei YF; Liu YC; Chen CY; Yu CJ
Int J Clin Pharmacol Ther; 2011 Oct; 49(10):587-93. PubMed ID: 21961483
[TBL] [Abstract][Full Text] [Related]
9. United States Food and Drug Administration Drug Approval summary: Gefitinib (ZD1839; Iressa) tablets.
Cohen MH; Williams GA; Sridhara R; Chen G; McGuinn WD; Morse D; Abraham S; Rahman A; Liang C; Lostritto R; Baird A; Pazdur R
Clin Cancer Res; 2004 Feb; 10(4):1212-8. PubMed ID: 14977817
[TBL] [Abstract][Full Text] [Related]
10. Gefitinib-Induced Interstitial Lung Disease in Korean Lung Cancer Patients.
Beom SH; Kim DW; Sim SH; Keam B; Park JH; Lee JO; Kim TM; Lee SH; Heo DS
Cancer Res Treat; 2016 Jan; 48(1):88-97. PubMed ID: 25761482
[TBL] [Abstract][Full Text] [Related]
11. Outcome in advanced non-small cell lung cancer patients with successful rechallenge after recovery from epidermal growth factor receptor tyrosine kinase inhibitor-induced interstitial lung disease.
Kashiwabara K; Semba H; Fujii S; Tsumura S
Cancer Chemother Pharmacol; 2017 Apr; 79(4):705-710. PubMed ID: 28258422
[TBL] [Abstract][Full Text] [Related]
12. Overview of the tolerability of gefitinib (IRESSA) monotherapy : clinical experience in non-small-cell lung cancer.
Forsythe B; Faulkner K
Drug Saf; 2004; 27(14):1081-92. PubMed ID: 15554744
[TBL] [Abstract][Full Text] [Related]
13. Gefitinib: new preparation. Non small-cell lung cancer: stricter assessment needed.
Prescrire Int; 2004 Oct; 13(73):168-70. PubMed ID: 15499696
[TBL] [Abstract][Full Text] [Related]
14. Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib.
Ando M; Okamoto I; Yamamoto N; Takeda K; Tamura K; Seto T; Ariyoshi Y; Fukuoka M
J Clin Oncol; 2006 Jun; 24(16):2549-56. PubMed ID: 16735708
[TBL] [Abstract][Full Text] [Related]
15. Relationship between epidermal growth factor receptor gene mutations and the severity of adverse events by gefitinib in patients with advanced non-small cell lung cancer.
Fujiwara Y; Kiura K; Toyooka S; Takigawa N; Tokumo M; Hotta K; Aoe M; Tabata M; Matsuo K; Date H; Tanimoto M
Lung Cancer; 2006 Apr; 52(1):99-103. PubMed ID: 16503086
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of safety and efficacy of gefitinib ('iressa', zd1839) as monotherapy in a series of Chinese patients with advanced non-small-cell lung cancer: experience from a compassionate-use programme.
Mu XL; Li LY; Zhang XT; Wang SL; Wang MZ
BMC Cancer; 2004 Aug; 4():51. PubMed ID: 15318946
[TBL] [Abstract][Full Text] [Related]
17. Gefitinib-related interstitial lung disease in Taiwanese patients with non-small-cell lung cancer.
Chang SC; Chang CY; Chang SJ; Yuan MK; Lai YC; Liu YC; Chen CY; Kuo LC; Yu CJ
Clin Lung Cancer; 2013 Jan; 14(1):55-61. PubMed ID: 22607779
[TBL] [Abstract][Full Text] [Related]
18. Gefitinib: a second look. Non-small cell lung cancer: still very disappointing.
Prescrire Int; 2009 Aug; 18(102):145-7. PubMed ID: 19739343
[TBL] [Abstract][Full Text] [Related]
19. Development of a skin rash within the first week and the therapeutic effect in afatinib monotherapy for EGFR-mutant non-small cell lung cancer (NSCLC): Okayama Lung Cancer Study Group experience.
Kudo K; Hotta K; Bessho A; Nogami N; Kozuki T; Kuyama S; Inoue K; Harita S; Okada T; Gemba K; Fujii M; Takigawa N; Oda N; Tanimoto M; Kiura K
Cancer Chemother Pharmacol; 2016 May; 77(5):1005-9. PubMed ID: 27029623
[TBL] [Abstract][Full Text] [Related]
20. Practical management of patients with non-small-cell lung cancer treated with gefitinib.
Shah NT; Kris MG; Pao W; Tyson LB; Pizzo BM; Heinemann MH; Ben-Porat L; Sachs DL; Heelan RT; Miller VA
J Clin Oncol; 2005 Jan; 23(1):165-74. PubMed ID: 15557594
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]